BlueChew vs. Hims for ED: Pricing, Treatments, and Reviews in 2025
BlueChew vs. Hims comparison
Since the first treatments hit the market more than 20 years ago, erectile dysfunction (ED) medications have become a multibillion-dollar industry. Many treatments are available, and with the popularity of online and mail-order services in recent years, two leaders are BlueChew and Hims.
Both companies offer different ED treatments and a similar business model, but what are the differences between BlueChew and Hims, and which one might be right for you?
BlueChew vs. Hims: Overview
Founded in 2017, Hims is a telemedicine platform that offers medical services and treatments related to sexual health, hair loss, anxiety, skin care, and more.
Hims connects its customers with licensed medical professionals who can diagnose and prescribe medications during a virtual appointment, including ED medications. Then, you can receive monthly deliveries of your Hims prescriptions.
BlueChew is another telemedicine platform founded in 2014 that offers online medical services and monthly subscriptions for ED medications. You'll meet with a licensed medical professional during a virtual visit and receive a prescription for an ED medication.
BlueChew specializes in chewable ED medications approved by the Food and Drug Administration (FDA), such as sildenafil, tadalafil, and vardenafil.
How to get started with BlueChew or Hims
BlueChew
Starting an order with BlueChew requires going to its website.
You'll select your preferred medication and plan and fill out a medical profile there. The questions cover basic information about your age and health and more specific ones that help the doctors ensure that BlueChew's medications are safe for you to use.
You'll also have to send them a picture of you holding a photo ID to verify your identity. Most medical reviews take just 1 to 2 days. After that, you'll get a supply of pills sent each month. You can also have your prescriptions filled at a compounding pharmacy near you.
Get started with BlueChew
Hims
The ordering and consultation process for Hims is very similar to BlueChew's. The main difference is that after filling out the form on the Hims website, you can get an immediate video, phone, or online chat consultation with a doctor.
Once they've determined the right medication for you, they'll write a prescription you can order from the Hims website or take to your preferred local or mail-order pharmacy.
BlueChew vs. Hims: Company reputation and customer reviews
BlueChew
BlueChew has been in business since 2014, and its rating on the Better Business Bureau (BBB) is low. However, there are only 14 reviews on the site. Most customer complaints seem to be related to shipping and billing issues. Some reviews show that people received orders they didn't want.
As of this writing, BlueChew has very few customer reviews available online besides the glowing ones on its website.
Hims
Hims has been available since 2017, and there are many negative reports from Hims customers who were unhappy about canceled or delayed appointments or persistent charges for medications they don't want. Positive reviews claim that Hims products were effective and that customer service was good.
Overall, Hims reviews are mixed.
Frequently asked questions about Hims and BlueChew
What is the difference between BlueChew and Hims?
If you have other conditions you want to address, like hair loss or skin concerns, you might want to try Hims because it has a much bigger product line.
If you have trouble swallowing whole pills, BlueChew's chewable tablets might be best for you. BlueChew will likely also be less expensive for most ED treatment options.
If you have other conditions you want to address, like hair loss or skin concerns, you might want to try Hims because it has a much bigger product line.
If you have trouble swallowing whole pills, BlueChew's chewable tablets might be best for you. BlueChew will likely also be less expensive for most ED treatment options.
Do you need a prescription to use BlueChew or Hims?
You don't need to bring a prescription to BlueChew or Hims to buy the products. With both services, you'll have an online consultation with a doctor who will write a prescription that you can fill on the website or at a pharmacy of your choice. With BlueChew, you'll have to use a compounding pharmacy.
You don't need to bring a prescription to BlueChew or Hims to buy the products. With both services, you'll have an online consultation with a doctor who will write a prescription that you can fill on the website or at a pharmacy of your choice. With BlueChew, you'll have to use a compounding pharmacy.
Are BlueChew treatments approved by the FDA?
BlueChew sells custom formulations of existing medications. While the active ingredients are FDA approved, the tablets you get from BlueChew are not.
BlueChew sells custom formulations of existing medications. While the active ingredients are FDA approved, the tablets you get from BlueChew are not.
Are Hims treatments approved by the FDA?
Hims ED treatments are all FDA approved, unlike some of its products used to treat other conditions like hair loss.
Hims ED treatments are all FDA approved, unlike some of its products used to treat other conditions like hair loss.
Is BlueChew better than Viagra?
BlueChew uses the same active ingredient as Viagra, meaning it will be likely be as effective. An older 2017 study found that chewable Viagra tablets, like BlueChew, had similar effects on the body compared to the more typical swallowable tablets. The authors wrote that chewable Viagra is a suitable alternative as people may find it easier to take.
BlueChew uses the same active ingredient as Viagra, meaning it will be likely be as effective. An older 2017 study found that chewable Viagra tablets, like BlueChew, had similar effects on the body compared to the more typical swallowable tablets. The authors wrote that chewable Viagra is a suitable alternative as people may find it easier to take.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025
Conference Call 8:00am ET, Wednesday August 20, 2025 WILMINGTON, Del., Aug. 13, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter 2025 financial results after the market closes on Tuesday, August 19, 2025 via press release, which will be available on the Company's website at The Company will host a conference call the following morning at 8:00am ET, Wednesday August 20, 2025. The Company requires additional time to compile certain information, including recent developments, into the Form 10-Q necessary for a complete presentation, which it is unable to complete without unreasonable effort. A live webcast of the conference call will be available on the Company's website at Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically +1-800-717-1738 or internationally +1-646-307-1865. About NRx Pharmaceuticals, Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRx has recently filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner's National Priority Voucher Program for the treatment of suicidal depression. The filing is based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and the Government of France, licensed under a data sharing agreement. Notice Regarding Forward-Looking StatementsThe information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise. For further information: Matthew Duffy Brian Korb Co-CEO, Hope Therapeutics, Inc. Managing Partner, astr Partners Chief Business Officer, NRx Pharmaceuticals, Inc. (917) 653-5122 mduffy@ View original content to download multimedia: SOURCE NRx Pharmaceuticals, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Miami Herald
18 minutes ago
- Miami Herald
Coffee that might have glass recalled from Dollar General stores in 48 states
Pieces of glass shouldn't be in any food, which is why Dollar General issued a not-food-in-your-food recall of Clover Velley Instant Coffee that might have glass. 'The recall is being initiated after a customer notified Dollar General employees about the potential issue,' the discount chain's FDA-posted recall notice said. 'Ingesting glass fragments may cause injury to the consumer, and these injuries may include damage to teeth, laceration of the mouth and throat, or perforation of the intestine. 'Dollar General is actively investigating the source of the glass contamination and apologizes for any inconvenience caused by this product issue.' This covers 8-ounce jars of Clover Valley Instant Coffee, lot No. L-5165 with a best by date of 12/14/2026 and lot Nos. L-5163 and L-5164 with best by dates 12/13/2026. These jars went to every state except Alaska and Hawaii. if you have the coffee, throw it out and reach out to Dollar General about a refund by emailing customercare@ or calling 888-309-9030, seven days a week, 7 a.m. to 2 a.m. Eastern time.
The Hill
18 minutes ago
- The Hill
FDA considers revoking Pfizer COVID vaccine for children under 5
The Food and Drug Administration is considering revoking the authorization of Pfizer's COVID-19 vaccine for healthy children under 5 years old, a move that would add another barrier for parents who want to vaccinate healthy children ahead of the respiratory virus season. Pfizer's three-dose shot for children between 6 months and 5 years old has long been available under an emergency use authorization (EUA). But according to the company, the FDA is weighing ending that authorization. 'We are currently in discussions with the agency on potential paths forward and have requested that the EUA for this age group remain in place for the 2025-2026 season,' Pfizer told The Hill. 'It is important to note that these deliberations are not related to the safety and efficacy of the vaccine which continues to demonstrate a favorable profile,' the company added. Pfizer expects the FDA to approve its vaccine for children ages 5 to 11 with the same limitations as Moderna and Novavax. The FDA in July approved Moderna's shot for children 6 months and older, but only if they have a health condition that puts them at increased risk for severe COVID-19. Novavax has never been approved for children under 12. Pfizer has had full FDA approval for its COVID-19 vaccine for individuals age 12 and older since 2022. It's not unusual for the FDA to revoke emergency authorization on a product if a competitor gains approval for an alternative, and Pfizer has not yet applied for full approval of its COVID-19 vaccine for the youngest age group. All COVID-19 vaccines were initially available only under emergency use authorizations— effectively special permissions given during an emergency if there are no FDA-approved alternatives available. But given the limitation on the Moderna shots, if Pfizer's authorization is pulled, healthy children under 5 years old will have no official options if their parents want to get them vaccinated. 'Parents already were struggling. We had parents, even last year, they had to drive two to three hours to get [COVID] vaccines for their kids. So already, access was an issue. Now it's just going to be abysmal,' said Fatima Khan, co-founder of the group Protect Their Future, which advocates for vaccine access for children. 'You're abandoning children right now … this is something that's so safe and so easy for them to just administer to our kids. Why can we not get it?' Khan said. In a statement to The Hill, the Department of Health and Human Services said it wouldn't comment on potential changes. 'The COVID-19 pandemic ended with the expiration of the federal public health emergency in May 2023. We do not comment on potential, future regulatory changes. Unless officially announced by HHS, discussion about future agency action should be regarded as pure speculation,' HHS spokesman Andrew Nixon said. In May, HHS Secretary Robert F. Kennedy Jr. said that the Centers for Disease Control and Prevention would no longer recommend COVID-19 vaccines for healthy children or pregnant women. The CDC then updated its immunization schedule to reflect that children with no underlying health condition 'may receive' COVID-19 vaccines after consulting with a health care provider. Kennedy has expressed personal antipathy towards the Moderna and Pfizer shots, calling them dangerous and unreliable. HHS also just announced it was pulling back on funding research involving the mRNA technology that was used to develop the vaccines in record time. State health officials said they have been told Moderna is ramping up supplies of its vaccine for the fall and will be able to meet demand if Pfizer's vaccine is no longer available for the youngest children. Providers who already pre-ordered Pfizer shots for the coming season will likely be able to switch to Moderna. But since the Moderna vaccine is only licensed for kids at risk of severe infection, pediatricians will have to offer them 'off label' for healthy kids with no guarantee it will be covered by insurance. 'We're hopeful that the clinical decision making allows them to request the vaccine and get it and have it covered by insurance. But it's just complicated,' said Claire Hannan, executive director of the Association of Immunization Managers, which represents state and local officials. 'The FDA just sort of went outside of the recommendation process in the way that it licensed the Moderna vaccine, and so there's a lot of confusion, and we're just sort of waiting for guidance from CDC on the ordering,' Hannan said. Infectious disease experts have said, and CDC data show, children under age 2 are at risk for severe COVID-19 infection even if they are otherwise healthy. Ayanna Bennett, director of the District of Columbia's Department of Health, said healthy kids should be able to live their best lives. If vaccination will keep them from getting seriously ill, it shouldn't be a question, she said. 'I want kids to not miss two weeks of school. I want kids not to be hospitalized, or in urgent care and miserable. We want them to be able to live their lives when there's no reason why they shouldn't,' Bennett told reporters during a briefing Wednesday. 'If I can prevent something, I should do it, and this is something where we absolutely have prevention available.'
